Takeda ordered to pay Bayer $155.19 million over patent infringement

pharmafile | February 6, 2019 | News story | Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate 

A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of a patent related to Baxalta’s haemophilia treatment Adynovate.

The decision came after jurors in Wilmington, Delaware rejected Baxalta’s argument that Bayer’s patent on Adynovate was invalid.

Bayer claims the infringement arose from Baxalta’s exclusive license agreement with San Francisco-based firm Nektar Therapeutics that had done research with Bayer and was aware of the patent.

The award covered the period from June 14, 2016 to Nov. 30, 2018. Jurors applied a royalty rate of 17.78 percent to a royalty base of $872.84 million to arrive at the $155.19 million damages award.

Haemophilia specialist Baxalta, was acquired by Shire in 2015 and became part of Takeda after the Japanese firm’s acquisition of Shire at the beginning of 2019.

Shire’s sales of Adynovate totalled $2.23 billion in the nine months ending 30 September 2018, $1.15 billion of which were made in the United States.

Louis Goss

Related Content

FDA grants Priority Review for Takeda’s cTTP treatment

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has …


Takeda collaboration to optimise biopharmaceutical manufacturing announced

A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering …

Bayer’s cardiovascular drug shows impressive Phase III results

Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events …

Latest content